Skip to content
10-Q

Quarterly Report

ENANTA PHARMACEUTICALS INC ENTA

0001193125-26-046502

← back to feed
Filed
Feb 11, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Feb 5, 2026 29.02M sh
Shares Diluted Q1 2026 · Dec 31, 2025 28.75M sh
Shares Diluted Q1 2026 · Dec 31, 2024 21.24M sh
Capex Q1 2026 · Dec 31, 2025 $143K
Capex Q1 2026 · Dec 31, 2024 $8.75M
Operating Cash Flow Q1 2026 · Dec 31, 2025 −$11.7M
Operating Cash Flow Q1 2026 · Dec 31, 2024 −$16.8M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $37.44M
Cash And Equivalents Q1 2026 · Sep 30, 2025 $32.3M
Stockholders Equity Q1 2026 · Dec 31, 2025 $126.59M
Stockholders Equity Q1 2026 · Sep 30, 2025 $64.72M
Stockholders Equity Q1 2026 · Dec 31, 2024 $111.82M
Stockholders Equity Q1 2026 · Sep 30, 2024 $128.81M
Current Liabilities Q1 2026 · Dec 31, 2025 $44.73M
Current Liabilities Q1 2026 · Sep 30, 2025 $48.56M
Total Liabilities Q1 2026 · Dec 31, 2025 $202.91M
Total Liabilities Q1 2026 · Sep 30, 2025 $216.02M
Current Assets Q1 2026 · Dec 31, 2025 $198.68M
Current Assets Q1 2026 · Sep 30, 2025 $204.34M
Total Assets Q1 2026 · Dec 31, 2025 $329.5M
Total Assets Q1 2026 · Sep 30, 2025 $280.73M
Eps Diluted Q1 2026 · Dec 31, 2025 −$0.42
Eps Diluted Q1 2026 · Dec 31, 2024 −$1.05
Eps Basic Q1 2026 · Dec 31, 2025 −$0.42
Eps Basic Q1 2026 · Dec 31, 2024 −$1.05
Sga Expense Q1 2026 · Dec 31, 2025 $9.01M
Sga Expense Q1 2026 · Dec 31, 2024 $12.85M
Rd Expense Q1 2026 · Dec 31, 2025 $20.86M
Rd Expense Q1 2026 · Dec 31, 2024 $27.66M
Net Income Q1 2026 · Dec 31, 2025 −$11.94M
Net Income Q1 2026 · Sep 30, 2025 −$81.89M
Net Income Q1 2026 · Dec 31, 2024 −$22.29M
Operating Income Q1 2026 · Dec 31, 2025 −$11.25M
Operating Income Q1 2026 · Dec 31, 2024 −$23.54M
Revenue Q1 2026 · Dec 31, 2025 $18.62M
Revenue Q1 2026 · Dec 31, 2024 $16.96M